Burdeau Jordan A, Stephenson Briana J K, Chavarro Jorge E, Mahalingaiah Shruthi, Preston Emma V, Hivert Marie-France, Oken Emily, Calafat Antonia M, Rifas-Shiman Sheryl L, Zota Ami R, James-Todd Tamarra
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
J Clin Endocrinol Metab. 2025 May 19;110(6):e1966-e1974. doi: 10.1210/clinem/dgae542.
Evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of developing cardiometabolic disease risk factors. Limited research has evaluated associations between PFAS, assessed during pregnancy, a sensitive window for maternal endocrine effects, and long-term maternal adiposity.
Estimate associations of early pregnancy measures of individual PFAS, and PFAS mixtures, with maternal adiposity in midlife.
We studied 547 Project Viva participants with measures of early pregnancy (mean gestation 10.0 weeks; mean age 32.5 years) plasma concentrations of 6 PFAS and midlife adiposity outcomes (mean follow-up 17.7 years; mean age 50.7 years), including weight, waist circumference (WC), trunk fat mass (TFM), and total body fat mass (TBFM). We used linear regression and Bayesian Kernel Machine Regression (BKMR).
Linear regression estimated higher midlife weight per doubling of perfluorooctane sulfonate (PFOS) (3.8 kg [95% CI: 1.6, 5.9]) and 2-(N-ethyl-perfluorooctane sulfonamido) acetate (2.3 kg [95% CI: 0.9, 3.7]). BKMR analyses of single PFAS plasma concentrations (comparing the 25th percentile concentration to the 75th percentile) showed a positive association between PFOS and midlife adiposity (weight: 7.7 kg [95% CI: 4.0, 11.5]; TFM: 1.2 kg [95% CI: 0.0, 2.3]; TBFM: 3.0 kg [95% CI: 0.8, 5.2]), but inverse associations with perfluorononanoate (weight: -6.0 kg [95% CI: -8.5, -3.5]; WC: -1.8 cm [95% CI: -3.2, -0.3]; TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.7, -0.3]) and perfluorohexane sulfonate (TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.6, -0.2]). No associations were observed with the overall PFAS mixture.
Select PFAS, assessed in pregnancy, may differentially affect maternal midlife adiposity, influencing later-life maternal cardiometabolic health.
有证据表明，接触全氟和多氟烷基物质（PFAS）会增加患心血管代谢疾病风险因素的风险。有限的研究评估了孕期（对母体内分泌影响的敏感时期）评估的PFAS与母体长期肥胖之间的关联。
估计孕早期个体PFAS及PFAS混合物指标与中年母体肥胖之间的关联。
我们对547名生命历程项目参与者进行了研究，这些参与者有孕早期（平均孕周10.0周；平均年龄32.5岁）6种PFAS的血浆浓度测量值以及中年肥胖指标（平均随访17.7年；平均年龄50.7岁），包括体重、腰围（WC）、躯干脂肪量（TFM）和全身脂肪量（TBFM）。我们使用了线性回归和贝叶斯核机器回归（BKMR）。
线性回归估计，全氟辛烷磺酸（PFOS）每增加一倍，中年体重增加3.8千克[95%置信区间：1.6，5.9]，2-（N-乙基全氟辛烷磺酰胺基）乙酸增加2.3千克[95%置信区间：0.9，3.7]。对单个PFAS血浆浓度进行BKMR分析（将第25百分位数浓度与第75百分位数浓度进行比较）显示，PFOS与中年肥胖之间存在正相关（体重：7.7千克[95%置信区间：4.0，11.5]；TFM：1.2千克[95%置信区间：0.0，2.3]；TBFM：3.0千克[95%置信区间：0.8，5.2]），但与全氟壬酸呈负相关（体重：-6.0千克[95%置信区间：-8.5，-3.5]；WC：-1.8厘米[95%置信区间：-3.2，-0.3]；TFM：-0.8千克[95%置信区间：-1.5，-0.1]；TBFM：-1.4千克[95%置信区间：-2.7，-0.3]）以及与全氟己烷磺酸呈负相关（TFM：-0.8千克[95%置信区间：-1.5，-0.1]；TBFM：-1.4千克[95%置信区间：-2.6，-0.2]）。未观察到与总体PFAS混合物存在关联。
孕期评估的特定PFAS可能对母体中年肥胖产生不同影响，进而影响母体晚年的心血管代谢健康。
